Navigation Links
Can we get there from here? Translating stem cell research into therapies
Date:5/25/2011

A new article published by Cell Press in the May 26 issue of the journal Neuron provides comprehensive insight into the current status of neural stem cell research and the sometimes labyrinthine pathways leading to stem cell-based therapies. The perspective on translating neural stem cell research into clinical therapeutics is part of a special issue of Neuron devoted to neural stem cells and neurogenesis and is published in collaboration with the May issue of Cell Stem Cell, which also has a selection of reviews on this topic.

Neurological disease and injury are a major cause of disability worldwide, and there is a pressing need to find reparative therapeutics for the central nervous system (CNS). Although stem cell therapies represent the frontier of regenerative medicine, the "bench to bedside" leap where scientific discoveries in the laboratory are translated to actual patient therapeutics faces many challenging hurdles.

"Stem cell research is one of the most rapidly developing areas of science and medicine," says study author Dr. Sally Temple from the Neural Stem Cell Institute in Rensselaer, New York. "The explosive rise in discoveries and technologies that we see in the basic research labs has yet to enter the pipeline, and there is an enormous gap between what we can do at the bench and what we see in the current clinical trials. It is imperative that we work towards making the process of translation more effective and affordable."

In their article, Dr. Temple and colleagues describe the current status of stem cell-based CNS therapies, analyze currently approved clinical trials, and discuss key issues associated with translational progress. The authors report that many basic scientists are struggling with low funding levels and that funding cutbacks substantially impede new research directions. They suggest that successfully transitioning from the lab to the clinics requires a comprehensive and collaborative team effort among researchers, clinicians, regulatory agencies, patient advocacy groups, ethics bodies, and industry, and they stress that pioneering this new partnership model is essential for smooth translational path that will improve the chance that the health benefits of research reach patients.

"There is no doubt that stem cell research and application is opening great opportunities in CNS regenerative therapies and, although our survey shows that we are still at relatively early stages of defining safety for human trials, stupendous strides are being made in preclinical studies," says Dr. Temple. "However, we must engage basic researchers and their institutions to ensure that they participate in the rewards of successful translation and benefit from revenue return that will fund further creative discoveries. We envision a much more concerted effort towards translation that would make the process more accessible and efficient, forging new private/public partnerships that will spread both risks and benefits in the process. Ultimately, the rewards of solving this problem could be seen at every level, from the next generation of young scientists to the patients. We need to take steps soon, as the challenge posed by neurological disorders is growing."


'/>"/>

Contact: Elisabeth Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related biology news :

1. Mating rivalry among furred and feathered: Variety is spice of life
2. Secret lives of the furred and feathered
3. Species unique to single island should not be rare there
4. Unknown animals nearly invisible but yet there
5. Macavity wasnt there! How absent reoviruses kill cancer
6. Theres a new officer in the infection control army
7. Urban gardeners beware: There may be lead in your soil and food
8. Why are there no hyenas in Europe?
9. Are there too many stem cell journals?
10. Scientists show theres nothing boring about watching paint dry
11. For pandas, there is a mountain high enough, there is a valley low enough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... ... May 26, 2016 , ... After ... Panama Inc. at the City of Knowledge in Panama, a 6 year-old ... in the US earlier this year following FDA approval of a second application ...
(Date:5/25/2016)... ... 2016 , ... The Ankle Plating System 3 and Small ... fractures of the distal tibia and fibula. This system marks Acumed's continued commitment ... is composed of seven plate families that span the lateral, medial, and posterior ...
(Date:5/25/2016)... Melbourne, FL (PRWEB) , ... May 25, 2016 , ... ... of eight she tore her cruciate ligament in her left knee. Lady’s owner Hannah ... , a central Florida board-certified veterinary surgeon, to repair her cruciate ligament and help ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... newly re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization ... imaging and image analysis. The re-branding components include a crisp, refreshed logo and ...
Breaking Biology Technology: